Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children

• Authors: Michelle Schoettler, Emory University; Elizabeth Stenger, Emory University; Kathleen Spencer, Childrens Healthcare Atlanta; Deborah Lutterman, Childrens Healthcare Atlanta; Savanah Rumbika, Emory University; Jayre Jones, Childrens Healthcare Atlanta; Ann Haight, Emory University; Suhag Parikh, Emory University; Muna Qayed, Emory University; Ben Watkins, Emory University; Lakshmanan Krishnamurti, Emory University; Kirsten Williams, Emory University; Satheesh Chonat, Emory University
• Journal Title: BLOOD ADVANCES
• Volume: Volume 7, Number 9
• Publisher: ELSEVIER | 2023-04-28, Pages 1784-1795
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1182/bloodadvances.2022008058
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Life Sciences & Biomedicine; Hematology; COMPLEMENT

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) and sickle cell disease (SCD) share features of endothelial and complement activation. Thus, we hypothesized that SCD is a risk factor for TA-TMA and that prehematopoietic cellular transplantation (HCT) markers of endothelial dysfunction and complement activation would be higher in patients with SCD. Children who underwent initial haploidentical or matched sibling donor HCT between January 2015 and June 2020 were included in this institutional review board–approved, single institution, retrospective study. Of the 115 children, 52 had SCD, and 63 underwent HCT for non-SCD indications. There was no significant difference in severe grade 3 to 4 acute graft-versus-host disease (GVHD) between recipients of HCT with or without SCD. The non-SCD cohort had significantly more cytomegalovirus-positive recipients, radiation-containing preparative regimens, and peripheral blood stem cell graft sources (P ≤ .05), all described risk factors for developing TA-TMA. Despite this, 7 of 52 patients (13%) with SCD developed TA-TMA compared with 1 of 63 patients (2%) without SCD (P = .015). Risk was highest in those who underwent haploidentical HCT (odds ratio [OR], 33; 95% confidence interval [CI], 1.4-793.2). Adjusting for HLA match, GVHD, post-HCT viral infection, stem cell source, and myeloablation, SCD remained a risk for developing TA-TMA (OR, 12.22; 95% CI, 1.15-129.6). In available pre-HCT samples, there was no difference in complement biomarkers between those with SCD and those without, though patients with SCD did have significantly higher levels of markers of endothelial activation, soluble vascular cell adhesion molecule 1, and P-selectin. In conclusion, children with SCD merit careful screening for TA-TMA after HCT, particularly those receiving a haploidentical HCT.